Navid Manouchehri1, Omid Mirmosayyeb1, Shervin Badihian1, Vahid Shaygannejad2. 1. Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran; Students' Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. 2. Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: shaygannejad@med.mui.ac.ir.
Abstract
BACKGROUND: Previous reports of cutaneous neoplastic lesions secondary to Fingolimod treatment among multiple sclerosis patients. OBJECTIVE: Reporting a case of cutaneous large cell lymphoma in a multiple sclerosis patient during Fingolimod treatment. METHOD: Case study. RESULT: Our patient developed CD30+ cutaneous large cell lymphoma two years after initiation of Fingolimod treatment and her symptoms regressed following the cessation of treatment. CONCLUSION: This report indicates that cutaneous lymphoid neoplasms should be considered a possible side effect among patients receiving Fingolimod.
BACKGROUND: Previous reports of cutaneous neoplastic lesions secondary to Fingolimod treatment among multiple sclerosispatients. OBJECTIVE: Reporting a case of cutaneous large cell lymphoma in a multiple sclerosispatient during Fingolimod treatment. METHOD: Case study. RESULT: Our patient developed CD30+ cutaneous large cell lymphoma two years after initiation of Fingolimod treatment and her symptoms regressed following the cessation of treatment. CONCLUSION: This report indicates that cutaneous lymphoid neoplasms should be considered a possible side effect among patients receiving Fingolimod.